- Home
- SPRO vs PAI Comparison
SPRO vs PAI Comparison
Compare SPRO & PAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- PAI
- Stock Information
- Founded
- SPRO 2013
- PAI 1973
- Country
- SPRO United States
- PAI United States
- Employees
- SPRO N/A
- PAI N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- PAI Trusts Except Educational Religious and Charitable
- Sector
- SPRO Health Care
- PAI Finance
- Exchange
- SPRO Nasdaq
- PAI Nasdaq
- Market Cap
- SPRO 136.7M
- PAI 118.3M
- IPO Year
- SPRO 2017
- PAI N/A
- Fundamental
- Price
- SPRO $2.24
- PAI $12.29
- Analyst Decision
- SPRO Buy
- PAI
- Analyst Count
- SPRO 2
- PAI 0
- Target Price
- SPRO $5.00
- PAI N/A
- AVG Volume (30 Days)
- SPRO 504.7K
- PAI 25.0K
- Earning Date
- SPRO 11-13-2025
- PAI 01-01-0001
- Dividend Yield
- SPRO N/A
- PAI 4.78%
- EPS Growth
- SPRO N/A
- PAI N/A
- EPS
- SPRO N/A
- PAI N/A
- Revenue
- SPRO $40,549,000.00
- PAI N/A
- Revenue This Year
- SPRO N/A
- PAI N/A
- Revenue Next Year
- SPRO N/A
- PAI N/A
- P/E Ratio
- SPRO N/A
- PAI N/A
- Revenue Growth
- SPRO N/A
- PAI N/A
- 52 Week Low
- SPRO $0.51
- PAI $10.59
- 52 Week High
- SPRO $3.22
- PAI $12.63
- Technical
- Relative Strength Index (RSI)
- SPRO 43.25
- PAI 31.72
- Support Level
- SPRO $2.33
- PAI $12.41
- Resistance Level
- SPRO $2.57
- PAI $12.55
- Average True Range (ATR)
- SPRO 0.15
- PAI 0.11
- MACD
- SPRO -0.03
- PAI -0.01
- Stochastic Oscillator
- SPRO 0.00
- PAI 5.03
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.